



- (51) **International Patent Classification:**
C12N 15/113 (2010.01) *A61K 31/713* (2006.01)
- (21) **International Application Number:**
PCT/US2023/070821
- (22) **International Filing Date:**
24 July 2023 (24.07.2023)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/391,860 25 July 2022 (25.07.2022) US
- (71) **Applicant:** AMGEN INC. [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).
- (72) **Inventors:** KILLION, Elizabeth, Ann; c/o Amgen Inc., Law Dept. - Patent Operations, One Amgen Center Drive, MS 28-5-A, Thousand Oaks, California 91320-1799 (US). HOLDER, Jerry, Ryan; c/o Amgen Inc., Law Dept. - Patent Operations, One Amgen Center Drive, MS 28-5-A, Thousand Oaks, California 91320-1799 (US). MEADE, Bryan; c/o Amgen Inc., Law Dept. - Patent Operations, One Amgen Center Drive, MS 28-5-A, Thousand Oaks, California 91320-1799 (US). MURRAY, Justin, K.; c/o Amgen Inc., Law Dept. - Patent Operations, One Amgen Center

Drive, MS 28-5-A, Thousand Oaks, California 91320-1799 (US). HOMANN, Oliver, R.; c/o Amgen Inc., Law Dept. - Patent Operations, One Amgen Center Drive, MS 28-5-A, Thousand Oaks, California 91320-1799 (US). GRIEGO, Briana, Renee; c/o Amgen Inc., Law Dept. - Patent Operations, One Amgen Center Drive, MS 28-5-A, Thousand Oaks, California 91320-1799 (US). VENIANT ELLISON, Murielle, Marie; c/o Amgen Inc., Law Dept. - Patent Operations, One Amgen Center Drive, MS 28-5-A, Thousand Oaks, California 91320-1799 (US).

- (74) **Agent:** ROADCAP, David et al.; One Amgen Center Drive, Law Dept - Patent Operations, MS 28-5-A, Thousand Oaks, California 91320-1799 (US).

- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

- (54) **Title:** RNAI CONSTRUCTS AND METHODS FOR INHIBITING FAM13A EXPRESSION




FIG. 6

- (57) **Abstract:** The present application relates to compositions and methods for modulating expression of Family with Sequence Similarity 13 Member A (FAM13A) protein. In particular, the present application relates to nucleic acid-based therapeutics for reducing *FAM13A* gene expression via RNA interference and methods of using such nucleic acid-based therapeutics to reduce abdominal adiposity, reduce body weight, reduce fat mass, improve metabolic parameters including insulin resistance and non-alcoholic steatohepatitis (NASH), and reduce risk of myocardial infarction.

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

14 March 2024 (14.03.2024)